CAR T cells manufactured with interleukin-15 would be predicted to exhibit an increased or enhanced release of pro-inflammatory and effector cytokines (such as Interferon-gamma and TNF-alpha) upon antigen stimulation compared to CAR T cells manufactured without interleukin-15.